Savara (NASDAQ:SVRA) Earns Overweight Rating from Analysts at Wells Fargo & Company

Wells Fargo & Company initiated coverage on shares of Savara (NASDAQ:SVRA - Free Report) in a report issued on Friday morning, MarketBeat.com reports. The brokerage issued an overweight rating and a $8.00 price target on the stock.

Other equities analysts have also issued reports about the company. HC Wainwright dropped their target price on Savara from $10.00 to $6.00 and set a "buy" rating for the company in a research note on Wednesday, November 13th. JMP Securities reaffirmed a "market outperform" rating and set a $9.00 price objective on shares of Savara in a research note on Thursday. Finally, Evercore ISI reiterated an "in-line" rating and set a $5.00 price objective (down from $7.00) on shares of Savara in a report on Wednesday, November 13th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, Savara presently has a consensus rating of "Moderate Buy" and a consensus price target of $9.86.

Savara Price Performance

Savara stock remained flat at $3.23 during mid-day trading on Friday. The company's stock had a trading volume of 2,253,347 shares, compared to its average volume of 1,275,570. The firm has a 50-day moving average price of $3.48 and a 200 day moving average price of $3.99. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70. The firm has a market cap of $554.33 million, a P/E ratio of -7.51 and a beta of 0.92. Savara has a one year low of $2.82 and a one year high of $5.70.

Savara (NASDAQ:SVRA - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, hitting the consensus estimate of ($0.11). Equities research analysts predict that Savara will post -0.45 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Joseph S. Mccracken bought 20,000 shares of the company's stock in a transaction dated Tuesday, November 19th. The stock was bought at an average price of $2.95 per share, with a total value of $59,000.00. Following the transaction, the director now owns 210,837 shares of the company's stock, valued at approximately $621,969.15. This trade represents a 10.48 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Matthew Pauls sold 54,702 shares of the stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $3.31, for a total value of $181,063.62. Following the transaction, the chief executive officer now directly owns 1,536,379 shares in the company, valued at approximately $5,085,414.49. This represents a 3.44 % decrease in their position. The disclosure for this sale can be found here. 5.13% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Choreo LLC acquired a new position in shares of Savara during the second quarter valued at $59,000. DRW Securities LLC bought a new stake in Savara in the 2nd quarter valued at about $62,000. Virtu Financial LLC acquired a new position in Savara during the 3rd quarter valued at about $67,000. Principal Financial Group Inc. grew its position in Savara by 64.4% in the 2nd quarter. Principal Financial Group Inc. now owns 17,795 shares of the company's stock worth $72,000 after purchasing an additional 6,973 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its stake in shares of Savara by 258.9% in the third quarter. BNP Paribas Financial Markets now owns 25,693 shares of the company's stock valued at $109,000 after purchasing an additional 18,534 shares during the period. 87.93% of the stock is owned by institutional investors and hedge funds.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.